TY - JOUR
T1 - Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity
AU - Clawson, Corbin
AU - Huang, Chien Tze
AU - Futalan, Diahnn
AU - Martin Seible, Daniel
AU - Saenz, Rebecca
AU - Larsson, Marie
AU - Ma, Wenxue
AU - Minev, Boris
AU - Zhang, Fiona
AU - Ozkan, Mihri
AU - Ozkan, Cengiz
AU - Esener, Sadik
AU - Messmer, Davorka
N1 - Funding Information:
This work is supported by the U.S. Army Medical Research and Materiel Command under Agreement No. W81XWH-07-1-0412 (D.M.); 5 U54 CA119335 from the National Institutes of Health/National Cancer Institute, (S.E.), the Swedish Research Council (VR) AI52731 and the Swedish International Development Cooperation Agency (SIDA) and VINNMER (Vinnova) (M.L.).
PY - 2010/10
Y1 - 2010/10
N2 - Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,. l-lactic-. co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ~20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer. From the Clinical Editor: In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.
AB - Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,. l-lactic-. co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ~20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer. From the Clinical Editor: In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.
KW - Dendritic cells
KW - HMGB1
KW - Immune stimulation
KW - PLGA nanoparticles
KW - Peptide conjugation
UR - http://www.scopus.com/inward/record.url?scp=77957167780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957167780&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2010.03.001
DO - 10.1016/j.nano.2010.03.001
M3 - Article
C2 - 20348031
AN - SCOPUS:77957167780
SN - 1549-9634
VL - 6
SP - 651
EP - 661
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 5
ER -